
    
      PRIMARY OBJECTIVES:

      I. To assess the impact of abiraterone acetate (abiraterone) and docetaxel on total quality
      of life between screening and month 12 of the study.

      SECONDARY OBJECTIVES:

      I. To assess prostate specific androgen (PSA) response rates across the entire population and
      compared between groups.

      II. To assess impact of abiraterone and docetaxel on additional quality of life measurements
      and quality of life trends throughout the duration of the study.

      III. To assess the potential clinical efficacy between treatment groups.
    
  